ACE-031 (1MG)

What Is ACE-031 and Why Buy It for Research?

Buy ACE-031 1mg in Switzerland for research into myostatin inhibition, muscle regulation, and TGF-β superfamily signaling. Specifically, ACE-031 (also known as Ramatercept) is a recombinant fusion protein engineered from the extracellular ligand-binding domain of human activin receptor type IIB (ActRIIB) linked to the Fc region of human immunoglobulin G1 (IgG1). Structurally, this fusion protein creates a soluble ActRIIB-Fc construct that functions as a decoy receptor for select TGF-β family ligands.

In scientific research, ACE-031 serves as a molecular tool for studying ligand-receptor interactions within the transforming growth factor-beta (TGF-β) superfamily. Researchers consider this fusion protein particularly valuable for investigating myostatin (GDF-8) signaling pathways and their role in skeletal muscle regulation. Furthermore, ACE-031 is supplied as a lyophilized powder in a 1mg format for laboratory use. Therefore, researchers seeking to source this fusion protein for their work will find it readily available through trusted suppliers.

ACE-031 Research Overview: Buy ACE-031 1mg in Switzerland for Myostatin Studies

Centrally, research into ACE-031 has focused on its function as a soluble ligand trap for myostatin and related negative regulators of muscle mass. Endogenously, myostatin (GDF-8) acts as a potent inhibitor of skeletal muscle growth by binding to ActRIIB receptors on muscle cells. ACE-031 disrupts this inhibitory signal by binding to myostatin and other ActRIIB ligands, including GDF11 and activins, before they can interact with endogenous cell-surface receptors.

Notably, research has demonstrated that ACE-031 promotes muscle growth by removing the biological “brakes” on myogenic development. Investigators have studied this fusion protein in various research contexts, including preclinical models of muscle wasting, cachexia, and neuromuscular disorders. Accordingly, researchers can buy ACE-031 1mg in Switzerland from Core Peptides to support their investigations into myostatin inhibition and muscle regulation pathways.

How Does ACE-031 Work in Research?

Mechanistically, ACE-031’s proposed action involves functioning as a soluble decoy receptor that sequesters TGF-β superfamily ligands. The ActRIIB extracellular domain within ACE-031 adopts a characteristic cysteine knot fold stabilized by disulfide bonds, creating a ligand-binding surface that accommodates mature TGF-β superfamily members. Consequently, when ACE-031 binds to myostatin, activins, and related ligands, it prevents these molecules from activating endogenous ActRIIB receptors on cell surfaces.

The Fc domain of ACE-031 serves multiple pharmaceutical purposes in this construct. Specifically, the human IgG1 Fc region naturally dimerizes, creating a bivalent molecule with two ActRIIB binding domains that increase ligand-binding avidity. Additionally, binding to the neonatal Fc receptor (FcRn) protects the protein from lysosomal degradation through a pH-dependent recycling mechanism, extending the circulating half-life to approximately 10 to 15 days. Thus, ACE-031 demonstrates a linear pharmacokinetic profile with sustained ligand sequestration capability.

Furthermore, the inclusion of the Fc domain facilitates purification using Protein A affinity chromatography during manufacturing and may retain partial Fc effector functions. A short peptide linker connects the ActRIIB extracellular domain to the IgG1 Fc domain, providing flexibility for independent domain movement and spatial separation between the ligand-binding and Fc domains.

Why Is ACE-031 Studied in Switzerland?

Primarily, researchers study ACE-031 because it represents a well-characterized ActRIIB-Fc fusion protein that enables investigation of myostatin and activin signaling pathways. In fact, this fusion protein offers a focused tool for studying ligand sequestration mechanisms and downstream signaling modulation within the TGF-β superfamily.

Preclinical studies have demonstrated that ACE-031 increases skeletal muscle mass and strength in normal mice and in murine models of muscular dystrophy. For example, research in the common marmoset showed that ACE-031 administration produced significant increases in body weight and lean body mass from baseline. Ultimately, researchers can buy ACE-031 1mg in Switzerland to access a research tool that may help uncover mechanisms underlying muscle regulation, tissue regeneration, and muscle-wasting pathways.

ACE-031 Research Areas in Laboratory Studies

Research Area	Focus	Evidence Level
Myostatin Inhibition	Ligand sequestration, ActRIIB signaling blockade	Mechanistic / In Vitro
Skeletal Muscle Growth	Muscle hypertrophy, fiber cross-sectional area	Animal / Preclinical
Muscle Wasting Disorders	Cachexia, age-related muscle loss, metabolic diseases	Animal / Preclinical
Neuromuscular Diseases	Duchenne muscular dystrophy (DMD), ALS models	Animal / Preclinical
TGF-β Superfamily Signaling	Ligand-receptor interactions, pathway modulation	Mechanistic / In Vitro
Bone and Fat Metabolism	Bone mineral density, adiponectin modulation	Emerging Research

ACE-031 Compared With Related Research Compounds

Compound	Research Focus	Mechanism / Target	Key Difference
ACE-031	Myostatin inhibition, muscle growth	ActRIIB-Fc decoy receptor (ligand trap)	Binds myostatin, activins, GDF11; long half-life
Follistatin	Myostatin inhibition	Natural binding protein	Endogenous inhibitor; does not strongly bind BMP9/10
Bimagrumab	Myostatin inhibition	Anti-ActRII monoclonal antibody	Competitively binds ActRII with greater affinity
ACE-083	Muscular dystrophy	Modified ligand trap	Does not bind BMP9/10; improved safety profile

Comparatively, ACE-031 differs from other myostatin inhibitors in its mechanism and ligand-binding profile. On the one hand, ACE-031 acts as a soluble receptor decoy that traps multiple TGF-β ligands, including myostatin, activins, and GDF11. On the other hand, follistatin is a natural binding protein that antagonizes myostatin through direct protein interaction. In contrast, ACE-031’s broader ligand-binding spectrum may offer more comprehensive pathway inhibition but has also been associated with safety considerations related to BMP inhibition.

Research Applications for ACE-031 in Switzerland

Scientists have investigated ACE-031 across several research domains:

• Myostatin Signaling Studies: Researchers use ACE-031 to investigate ligand-receptor interactions and downstream signaling modulation within the TGF-β superfamily.
• Muscle Growth and Hypertrophy Research: Studies have examined ACE-031’s potential to increase skeletal muscle mass and strength in various preclinical models.
• Muscle Wasting Disorders: Preclinical research has explored ACE-031’s potential in models of cancer cachexia, age-related muscle loss, and metabolic diseases.
• Neuromuscular Disease Research: Clinical studies have investigated ACE-031 in Duchenne muscular dystrophy (DMD) patients.
• Receptor-Ligand Interaction Studies: ACE-031 serves as a reference construct for investigating fusion protein and decoy receptor mechanisms.

Evidently, researchers can buy ACE-031 1mg in Switzerland for these applications, as it is a valuable addition to any laboratory toolkit focused on muscle regulation and TGF-β signaling research.

ACE-031 Product Specifications

Specification	Details
Product Name	ACE-031 (Ramatercept)
Alternative Names	ActRIIB-Fc, Myostatin inhibitory peptide 7
Amount	1mg
Form	Lyophilized powder
Purity	Not verified
Protein Type	Recombinant ActRIIB-Fc fusion protein
Protein Composition	Extracellular domain of human ActRIIB fused to Fc region of human IgG1
Molecular Formula	Not verified (complex fusion protein)
Molecular Weight	Not verified (monomer ~50-60 kDa; dimer ~100-120 kDa)
CAS Number	Not provided
Research Category	Muscle & Performance
Research Use	Laboratory research use only
CoA	Available upon request (not verified)
Storage	Lyophilized powder should be stored desiccated at -20°C or below

How to Evaluate ACE-031 Quality for Research

When sourcing ACE-031 fusion protein for laboratory research, researchers should consider several quality indicators:

• Identity Confirmation: Analytical techniques such as mass spectrometry and SDS-PAGE should confirm the protein’s molecular weight and fusion protein structure.
• Purity Assessment: High-performance liquid chromatography (HPLC) and size-exclusion chromatography (SEC) can provide information about protein purity.
• Batch Traceability: Lot numbers and batch information enable researchers to track specific production runs.
• Certificate of Analysis: A CoA should accompany the product, detailing analytical testing results.
• Labeling Accuracy: Proper labeling should clearly indicate the product name, amount, protein type, and storage recommendations.
• Storage Conditions: Appropriate storage at -20°C or below in desiccated conditions helps maintain protein stability.

Understanding the Certificate of Analysis

Typically, a Certificate of Analysis (CoA) accompanies research proteins and provides information about the specific batch’s analytical testing. For example, a CoA may include product identity confirmation, purity percentage as determined by HPLC or SEC, batch or lot number for traceability, analytical methods used (e.g., mass spectrometry, SDS-PAGE), and a physical description of the product.

Nevertheless, it is important to note that a CoA does not establish safety, efficacy, therapeutic effectiveness, or suitability for human use. Instead, it serves as a quality control document that helps researchers verify the identity and purity of the protein they are using in their laboratory investigations.

Storage and Stability of ACE-031

Core Peptides supplies ACE-031 as a lyophilized (freeze-dried) powder. To maintain stability and integrity:

• Store the lyophilized powder desiccated at -20°C or below
• Avoid repeated freeze-thaw cycles
• Reconstitute only immediately before use with appropriate sterile solvents
• Gently swirl to dissolve; do not vortex
• Filter sterilize if required (e.g., 0.22 µm) immediately prior to use
• Aliquot and store reconstituted solutions at -20°C (or lower)
• Protect from light and moisture

Frequently Asked Questions About Buying ACE-031 1mg in Switzerland

What is ACE-031?

Specifically, ACE-031 (Ramatercept) is a recombinant fusion protein consisting of the extracellular ligand-binding domain of human activin receptor type IIB (ActRIIB) linked to the Fc region of human IgG1.

What is ACE-031 researched for?

Primarily, researchers study ACE-031 for its role as a soluble decoy receptor that binds myostatin and related TGF-β superfamily ligands. Studies have investigated its effects on muscle growth, muscle wasting disorders, and neuromuscular diseases.

How does ACE-031 work?

Mechanistically, ACE-031 functions as a ligand trap that binds to myostatin, activins, and GDF11, preventing these ligands from interacting with endogenous ActRIIB receptors. Consequently, it inhibits the signaling pathways that naturally limit muscle growth.

What is the molecular weight of ACE-031?

Not verified. As a complex fusion protein, the monomer is approximately 50-60 kDa and the dimer is approximately 100-120 kDa.

What is the CAS number of ACE-031?

Not provided. ACE-031 is a recombinant fusion protein, not a small molecule peptide with a registered CAS number.

Is ACE-031 synthetic?

Yes, ACE-031 is a recombinant fusion protein produced through protein engineering and recombinant expression systems.

What research exists on ACE-031?

Research on ACE-031 includes preclinical studies in mice and non-human primates, a Phase 1 study in healthy postmenopausal women, and a Phase 2 clinical trial in boys with Duchenne muscular dystrophy.

What is the difference between ACE-031 and other myostatin inhibitors?

ACE-031 is a soluble ActRIIB-Fc decoy receptor that traps multiple TGF-β ligands, whereas other inhibitors like follistatin are natural binding proteins or monoclonal antibodies like bimagrumab that target specific pathways.

Is ACE-031 approved as a medicine?

No. Regulatory authorities have not approved ACE-031 as a medicine, pharmaceutical, or therapeutic agent. Clinical development was discontinued due to safety concerns.

Is ACE-031 intended for human use?

No. ACE-031 is intended for laboratory research use only and is not for human consumption, injection, or therapeutic application.

Where can I buy ACE-031 1mg in Switzerland?

You can buy ACE-031 1mg in Switzerland from Core Peptides, a trusted research peptide and protein supplier serving the Swiss scientific community.

How should researchers evaluate ACE-031 quality?

Researchers should look for identity confirmation via mass spectrometry, purity data from HPLC/SEC, batch traceability, and a Certificate of Analysis.

Related Research Compounds

Researchers interested in ACE-031 may also find the following related compounds relevant to their work:

• Follistatin — A natural myostatin-binding protein that antagonizes TGF-β superfamily ligands through direct protein interaction.
• BPC-157 — A peptide researched for tissue healing, gastrointestinal health, and angiogenesis.
• TB-500 — A Thymosin Beta 4 fragment researched for tissue repair and wound healing.
• GHK-Cu — A copper-binding peptide researched for skin regeneration, wound healing, and anti-aging applications.

Explore Muscle & Performance

ACE-031 belongs to the Muscle & Performance category of research compounds. Muscle & Performance products are studied for their potential roles in muscle growth, myostatin inhibition, and performance-related mechanisms. Generally, researchers who buy ACE-031 1mg in Switzerland often pair it with related compounds in this category to explore complementary pathways in muscle regulation and tissue remodeling.

Further Research

For researchers seeking to deepen their understanding of ACE-031 and its research applications, the following areas may warrant further investigation:

• The relationship between ACE-031-mediated myostatin inhibition and specific downstream signaling pathways
• Comparative studies between ACE-031 and other ActRIIB-Fc fusion proteins in various research models
• The potential role of ACE-031 in modulating bone and fat metabolism
• Mechanistic studies on ACE-031’s interaction with different TGF-β superfamily ligands
• Exploration of ACE-031’s effects on different cell types and tissue systems

Research Disclaimer

ACE-031 is a research protein supplied for laboratory research use only. Researchers must not use it for human consumption, injection, or any form of therapeutic application. Moreover, this product is not a medicine, pharmaceutical, or medical device. Furthermore, Swissmedic, the FDA, EMA, or any other regulatory authority have not approved it for human use. Researchers should consult Swissmedic for applicable regulations and guidance on research protein handling in Switzerland.

Generally, the information provided on this page is for educational and scientific reference purposes only. Therefore, it does not constitute medical advice, treatment recommendations, or dosing instructions. Ultimately, researchers bear the responsibility for ensuring that their use of this product complies with all applicable laws, regulations, and institutional guidelines.

Finally, all research involving proteins should be conducted by qualified personnel in appropriate laboratory settings with proper safety protocols.